U.S. Stock Earnings Reports & Market News
Executive Summary Merck & Co Inc reported solid financial performance for the third quarter of FY2025, with revenue increasing by 4.0% year-over-year (YoY) from $16.66 billion to $17.28 billion. Despite this revenue growth, net income experienced a marginal decrease of…
Executive Summary Pfizer Inc reported robust financial performance for Q3 FY2024, with revenue increasing by 31.4% year-over-year (YoY) from $13.49 billion in Q3 FY2023 to $17.70 billion. Net income also saw a significant rise, reaching $4.48 billion, a substantial turnaround…
Executive Summary In the third quarter of fiscal year 2025, Eli Lilly and Company reported a substantial increase in revenue, reaching $17.6 billion, representing a 54.4% growth compared to the same period last year. Net income also saw a significant…
Executive Summary The third quarter of FY2025 for Bristol-Myers Squibb (BMY) demonstrated a resilient revenue performance with a 3% increase year-over-year, reaching $12.2 billion. Net earnings attributable to BMS rose significantly to $2.2 billion, reflecting improved operational efficiency and product…
Executive Summary Johnson & Johnson reported solid financial performance for the third quarter of FY2025, with revenue increasing by 6.6% year-over-year (YoY) from $22.47 billion to $23.99 billion. Net income remained stable at approximately $5.15 billion, reflecting resilient profitability amidst…
Executive Summary The company’s revenue for the second quarter of FY2025 slightly decreased by 0.3% compared to the same period last year, from $12.20 billion to $12.27 billion. Net income improved significantly from a net loss of $10.23 billion in…
Executive Summary The first quarter of fiscal year 2025 for Bristol-Myers Squibb (NYSE: BMY) shows a challenging start with a 3% decline in total revenue compared to the same period last year, primarily driven by lower sales in legacy products.…
Executive Summary In FY2024, AbbVie Inc. reported total net revenues of $56.33 billion, representing a 3.7% increase compared to $54.32 billion in FY2023. Despite revenue growth, net earnings declined by 12.1% from $4.87 billion to $4.28 billion, primarily due to…
Executive Summary This comprehensive financial report for Bristol-Myers Squibb (BMY) for FY2024 highlights significant growth in revenue driven by robust sales across key portfolios, despite a substantial net loss primarily due to acquisition-related charges and impairments. The company’s strategic acquisitions,…
Executive Summary Merck & Co Inc reported solid financial performance for the second quarter of FY2025, with a net income of $4.43 billion, maintaining stability compared to the prior year despite a slight decline in revenue. The company’s revenue decreased…
Executive Summary In the first quarter of FY2025, Merck & Co. reported a net income of $5.08 billion, representing a 6.6% increase compared to $4.76 billion in the same period last year. Revenue slightly decreased by 1.5%, from $15.78 billion…
Executive Summary Merck & Co. reported a remarkable increase in net income for FY2024, reaching $17.1 billion, representing a 4,583% rise compared to the prior year. Revenue also grew by 6.8% to $64.2 billion, driven by strong pharmaceutical sales, including…
Executive Summary Johnson & Johnson (JNJ) reported solid financial performance for the second quarter of FY2025, with revenue reaching $23.74 billion, representing a 5.7% increase compared to $22.45 billion in the same period last year. Net income from continuing operations…
Executive Summary Johnson & Johnson, a leading global healthcare company, reported its first quarter of fiscal year 2025 with total revenue of $21.9 billion, representing a 2.4% increase compared to the same period last year. Net earnings reached $11 billion,…
Executive Summary In Q2 FY2025, Eli Lilly and Company demonstrated robust revenue growth, increasing by 37.7% compared to the same period last year, driven by strong product sales and expanded market presence. Net income also rose significantly, reflecting improved operational…
Executive Summary In the first quarter of fiscal year 2025, Eli Lilly and Company demonstrated robust financial performance with a significant surge in revenue and net income. Revenue grew by 63% compared to the prior year, driven primarily by increased…
Executive Summary ELI Lilly and Company reported robust financial performance for FY2024, with total revenue reaching $45.04 billion, representing a 32% increase compared to FY2023. Net income surged by 102%, rising to $10.59 billion, driven by strong product sales and…
Key Metrics (Historical Comparisons) Period Revenue (USD) Gross Profit (USD) Operating Income (USD) Net Income (USD) EPS (Diluted) Total Assets (USD Billions) Total Debt (USD Billions) Cash & Equivalents (USD Billions) Q2 FY2025 14.653B 9.42B 3.70B 2.89B 0.51 unknown unknown…
Key Metrics (Historical Comparisons) Period Revenue (USD) Gross Profit (USD) Operating Income (USD) Net Income (USD) EPS (Diluted) Total Assets (USD, millions) Total Debt (USD, millions) Equity (USD, millions) Q1 FY2025 13.715 billion 9.827 billion 4.624 billion 2.967 billion 0.520…
Key Metrics (Historical Comparison) Year Revenue (USD) Gross Profit (USD) Operating Income (USD) Net Income (USD) EPS (Diluted) 2024 63.63B 41.85B 11.11B 8.03B 1.41 2023 59.55B 30.34B 3.27B 2.13B 0.37 2022 100.33B 62.09B 35.97B 31.37B 5.59 2021 81.29B 46.87B 25.60B…